The AACR-Conquer Cancer Foundation of ASCO Young Investigator Award for Translational Cancer Research provides funding to physician-scientists to encourage and promote quality research in clinical oncology.

2024 Grantee

Research

Breast cancer stands out among epithelial malignancies due to its distinct genomic landscape, which is characterized by a high degree of structural variation and genomic instability. These genomic changes produce nucleotide sequences that are highly specific to cancer cells; occasionally in the form of expressed fusion RNAs. Dr. Priedigkeit will merge advances in genomic discovery and gene therapy to better define the landscape of fusion RNAs in metastatic breast cancer and credential novel gene therapy approaches to exploit these sequences as recruitment biomolecules for cytotoxic payload delivery.

Biography

Dr. Priedigkeit received his medical and doctoral degrees (MD/PhD) from the University of Pittsburgh School of Medicine. His thesis applied translational genomics to discover acquired molecular dependencies in metastatic breast cancers. He is currently a medical oncology fellow at Dana-Farber Cancer Institute and a postdoctoral scholar at the Broad Institute of MIT & Harvard. In his clinical practice, he sees patients with breast cancer. His research aims to merge computational and genomic sciences with technology development to improve how we understand and treat advanced cancers.

Acknowledgment of Support

“The AACR-Conquer Cancer, the ASCO Foundation Young Investigator Award for Translational Cancer Research will help catalyze my development as an independent physician scientist focused on applying genomic technologies to improve how we care for patients with advanced malignancies.”